Ascentage Pharma Group International (AAPG)vsJohnson & Johnson (JNJ)
AAPG
Ascentage Pharma Group International
$15.58
-1.83%
HEALTHCARE · Cap: $1.41B
JNJ
Johnson & Johnson
$269.21
-0.01%
HEALTHCARE · Cap: $640.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 15139% more annual revenue ($97.93B vs $642.63M). JNJ leads profitability with a 21.5% profit margin vs -228.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
AAPG
Avoid25
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 29.3% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Trading at 17.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.76 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
AAPG profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.67 — expect wider price swings.
AAPG is growing revenue faster at 29.3% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 25/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?